{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:33:59Z","timestamp":1792784039822,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"UT Southwestern Simmons Cancer Center Grant","award":["NIH 5P30 CA 142543"],"award-info":[{"award-number":["NIH 5P30 CA 142543"]}],"id":[{"id":"https:\/\/ror.org\/03cbz4r60","id-type":"ROR","asserted-by":"crossref"}]},{"name":"American Cancer Society and the Simmons Cancer Center","award":["ACS-IRG-02-196"],"award-info":[{"award-number":["ACS-IRG-02-196"]}],"id":[{"id":"https:\/\/ror.org\/03cbz4r60","id-type":"ROR","asserted-by":"crossref"}]},{"name":"UT Southwestern High Impact\/High Risk funds, NINDS K99\/R00","award":["R00NS073735"],"award-info":[{"award-number":["R00NS073735"]}],"id":[{"id":"https:\/\/ror.org\/05byvp690","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11307-019-01327-4","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T22:44:22Z","timestamp":1551307462000},"page":"1138-1146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Evaluation of l-1-[18F]Fluoroethyl-Tryptophan for PET Imaging of Cancer"],"prefix":"10.1007","volume":"21","author":[{"given":"Yangchun","family":"Xin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Ping","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hancheng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"key":"1327_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nrd3793","volume":"12","author":"L V\u00e9csei","year":"2013","unstructured":"V\u00e9csei L, Szal\u00e1rdy L, F\u00fcl\u00f6p F, Toldi J (2013) Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 12:64\u201382","journal-title":"Nat Rev Drug Discov"},{"key":"1327_CR2","doi-asserted-by":"publisher","first-page":"8762","DOI":"10.1021\/acs.jmedchem.5b00461","volume":"58","author":"AB Dounay","year":"2015","unstructured":"Dounay AB, Tuttle JB, Verhoest PR (2015) Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway. J Med Chem 58:8762\u20138782","journal-title":"J Med Chem"},{"key":"1327_CR3","doi-asserted-by":"publisher","first-page":"43S","DOI":"10.2967\/jnumed.107.045930","volume":"49","author":"C Plathow","year":"2008","unstructured":"Plathow C, Weber WA (2008) Tumor cell metabolism imaging. J Nucl Med 49:43S\u201363S","journal-title":"J Nucl Med"},{"key":"1327_CR4","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.4161\/cbt.6.8.4446","volume":"6","author":"V Karanikas","year":"2007","unstructured":"Karanikas V, Zamanakou M, Kerenidi T, Dahabreh J, Hevas A, Nakou M, Gourgoulianis KI, Germenis AE (2007) Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 6:1258\u20131262","journal-title":"Cancer Biol Ther"},{"key":"1327_CR5","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","volume":"9","author":"C Uyttenhove","year":"2003","unstructured":"Uyttenhove C, Pilotte L, Th\u00e9ate I, Stroobant V, Colau D, Parmentier N, Boon T, van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269\u20131274","journal-title":"Nat Med"},{"key":"1327_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1593\/neo.04658","volume":"7","author":"S Astigiano","year":"2005","unstructured":"Astigiano S, Morandi B, Costa R, Mastracci L, D'Agostino A, Ratto GB, Melioli G, Frumento G (2005) Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 7:390\u2013396","journal-title":"Neoplasia"},{"key":"1327_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-015-0094-9","volume":"3","author":"YW Moon","year":"2015","unstructured":"Moon YW, Hajjar J, Hwu P, Naing A (2015) Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J Immunother Cancer 3:51","journal-title":"J Immunother Cancer"},{"key":"1327_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejca.2017.01.011","volume":"76","author":"L Brochez","year":"2017","unstructured":"Brochez L, Chevolet I, Kruse V (2017) The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur J Cancer 76:167\u2013182","journal-title":"Eur J Cancer"},{"key":"1327_CR9","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/JCO.2017.35.15_suppl.3003","volume":"35","author":"RP Perez","year":"2017","unstructured":"Perez RP, Riese MJ, Lewis KD, Saleh MN, Adil Daud JB (2017) Epacadostat plus nivolumab in patients with advanced solid tumors: preliminary phase I\/II results of ECHO-204 [ASCO abstract 3003]. J Clin Oncol 35:3003\u20133003","journal-title":"J Clin Oncol"},{"issue":"13 Suppl","key":"1327_CR10","first-page":"AM2017","volume":"77","author":"Y Zakharia","year":"2017","unstructured":"Zakharia Y, McWilliams R, Shaheen M, Grossman K, Drabick J, Milhem M, Rixie O, Khleif S, Lott R, Kennedy E, David Munn NV, CL (2017) Interim analysis of the phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma. [AACR abstract CT117]. Cancer Res 77(13 Suppl):AM2017\u2013ACT117","journal-title":"Cancer Res"},{"key":"1327_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2014.00673","volume":"5","author":"M Platten","year":"2015","unstructured":"Platten M, von Knebel Doeberitz N, Oezen I et al (2015) Cancer immunotherapy by targeting IDO1\/TDO and their downstream effectors. Front Immunol 5:1\u20137","journal-title":"Front Immunol"},{"key":"1327_CR12","doi-asserted-by":"publisher","first-page":"6985","DOI":"10.1158\/1078-0432.CCR-11-1331","volume":"17","author":"J Godin-Ethier","year":"2011","unstructured":"Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R (2011) Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 17:6985\u20136991","journal-title":"Clin Cancer Res"},{"key":"1327_CR13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674","journal-title":"Cell"},{"key":"1327_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2967\/jnumed.108.058776","volume":"50","author":"C Juh\u00e1sz","year":"2009","unstructured":"Juh\u00e1sz C, Muzik O, Lu X et al (2009) Quantification of tryptophan transport and metabolism in lung tumors using PET. J Nucl Med 50:356\u2013363","journal-title":"J Nucl Med"},{"key":"1327_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.nucmedbio.2016.02.001","volume":"43","author":"X Huang","year":"2016","unstructured":"Huang X, Xiao X, Gillies RJ, Tian H (2016) Design and automated production of 11C-alpha-methyl-l-tryptophan (11C-AMT). Nucl Med Biol 43:303\u2013308","journal-title":"Nucl Med Biol"},{"key":"1327_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s11307-016-1024-z","volume":"19","author":"Y Xin","year":"2017","unstructured":"Xin Y, Cai H (2017) Improved radiosynthesis and biological evaluations of L- and D-1-[18F]fluoroethyl-tryptophan for PET imaging of IDO-mediated kynurenine pathway of tryptophan metabolism. Mol Imaging Biol 19:589\u2013598","journal-title":"Mol Imaging Biol"},{"key":"1327_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2967\/jnumed.116.179994","volume":"58","author":"SK Michelhaugh","year":"2017","unstructured":"Michelhaugh SK, Muzik O, Guastella AR, Klinger NV, Polin LA, Cai H, Xin Y, Mangner TJ, Zhang S, Juh\u00e1sz C, Mittal S (2017) Assessment of tryptophan uptake and kinetics using 1-(2- 18 F-fluoroethyl)-l-tryptophan and \u03b1- 11 C-methyl-l-tryptophan PET imaging in mice implanted with patient-derived brain tumor xenografts. J Nucl Med 58:208\u2013213","journal-title":"J Nucl Med"},{"key":"1327_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.nucmedbio.2016.03.001","volume":"43","author":"J Henrottin","year":"2016","unstructured":"Henrottin J, Lemaire C, Egrise D, Zervosen A, Van den Eynde B, Plenevaux A, Franci X, Goldman S, Andr\u2019Luxen E, Luxen A, Jean Henrottin CL et al (2016) Fully automated radiosynthesis of 1-[18F]FETrp, a potential substrate for indoleamine 2,3-dioxygenase PET imaging. Nucl Med Biol 43:379\u2013389","journal-title":"Nucl Med Biol"},{"key":"1327_CR19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.apradiso.2011.11.062","volume":"70","author":"T Sun","year":"2012","unstructured":"Sun T, Tang G, Tian H, Wang X, Chen X, Chen Z, Wang SC (2012) Radiosynthesis of 1-[18F]fluoroethyl-L-tryptophan as a novel potential amino acid PET tracer. Appl Radiat Isot 70:676\u2013680","journal-title":"Appl Radiat Isot"},{"key":"1327_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2967\/jnumed.111.096289","volume":"53","author":"SD Kramer","year":"2012","unstructured":"Kramer SD, Mu L, Muller A, Keller C, Kuznetsova OF, Schweinsberg C, Franck D, Muller C, Ross TL, Schibli R, Ametamey SM (2012) 5-(2-18F-fluoroethoxy)-L-tryptophan as a substrate of system L transport for tumor imaging by PET. J Nucl Med 53:434\u2013442","journal-title":"J Nucl Med"},{"key":"1327_CR21","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1021\/acs.jmedchem.6b00057","volume":"59","author":"A Chiotellis","year":"2016","unstructured":"Chiotellis A, Mu A, Ro SL et al (2016) Synthesis, radiolabeling, and biological evaluation of 5-hydroxy- 2-[18F]fluoroalkyl-tryptophan analogues as potential PET radiotracers for tumor imaging. J Med Chem 59:5324\u20135340","journal-title":"J Med Chem"},{"key":"1327_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1021\/acs.jmedchem.7b01245","volume":"61","author":"BD Zlatopolskiy","year":"2018","unstructured":"Zlatopolskiy BD, Zischler J, Urusova EA et al (2018) Discovery of 7-[18 F]fluorotryptophan as a novel positron emission tomography (PET) probe for the visualization of tryptophan metabolism in vivo. J Med Chem 61:189\u2013206","journal-title":"J Med Chem"},{"key":"1327_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1021\/ml500385d","volume":"6","author":"J Henrottin","year":"2015","unstructured":"Henrottin J, Zervosen A, Lemaire C, Sapunaric F, Laurent S, van den Eynde B, Goldman S, Plenevaux A, Luxen A (2015) N1-fluoroalkyltryptophan analogues: synthesis and in vitro study as potential substrates for indoleamine 2,3-dioxygenase. ACS Med Chem Lett 6:260\u2013265","journal-title":"ACS Med Chem Lett"},{"key":"1327_CR24","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4046\/trd.2009.66.4.274","volume":"66","author":"GM Park","year":"2009","unstructured":"Park GM, Lee S-M, Yim J-J, Yang S-C, Yoo CG, Lee C-T, Han SK, Young-Soo Shim YWK (2009) Expression of COX-2 and IDO by uteroglobin transduction in NSCLC cell lines transduction in NSCLC cell lines. Tuberc Respir Dis (Seoul) 66:274\u2013279","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"1327_CR25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0925-4439(99)00096-4","volume":"1500","author":"Y Kudo","year":"2000","unstructured":"Kudo Y, Boyd CAR (2000) Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection. Biochim Biophys Acta - Mol Basis Dis 1500:119\u2013124","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"key":"1327_CR26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.juro.2016.09.117","volume":"197","author":"T Bach-Gansmo","year":"2017","unstructured":"Bach-Gansmo T, Nanni C, Nieh PT, Zanoni L, Bogsrud TV, Sletten H, Korsan KA, Kieboom J, Tade FI, Odewole O, Chau A, Ward P, Goodman MM, Fanti S, Schuster DM, Willoch F (2017) Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) positron emission tomography\/computerized tomography imaging in the staging of biochemically recurrent prostate Cancer. J Urol 197:676\u2013683","journal-title":"J Urol"},{"key":"1327_CR27","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1200\/JCO.2017.35.15_suppl.3066","volume":"35","author":"GG Jha","year":"2017","unstructured":"Jha GG, Gupta S, Tagawa ST, Koopmeiners JS, Vivek S, Dudek AZ, Cooley SA, Blazar BR, JSM (2017) A phase II randomized, double-blind study of sipuleucel-T followed by IDO pathway inhibitor, indoximod, or placebo in the treatment of patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 35:3066\u20133066","journal-title":"J Clin Oncol"},{"key":"1327_CR28","unstructured":"Masonic Cancer Center, University of Minnesota. Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer. Available from: \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01560923\n\n. NLM identifier: NCT01560923. Accessed 21 Feb 2019"},{"key":"1327_CR29","first-page":"1281","volume":"5","author":"Q Wang","year":"2015","unstructured":"Wang Q, Holst J (2015) L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia. Am J Cancer Res 5:1281\u20131294","journal-title":"Am J Cancer Res"},{"key":"1327_CR30","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.semcancer.2005.04.005","volume":"15","author":"BC Fuchs","year":"2005","unstructured":"Fuchs BC, Bode BP (2005) Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 15:254\u2013266","journal-title":"Semin Cancer Biol"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-019-01327-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-019-01327-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-019-01327-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T19:22:27Z","timestamp":1582744947000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-019-01327-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1327"],"URL":"https:\/\/doi.org\/10.1007\/s11307-019-01327-4","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,27]]},"assertion":[{"value":"27 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}